Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12170572 | 0.70 | EIF4E (0.46) | GPR119EIF4EMKNK1MKNK2CYP2C9 | |
| SCHEMBL4482969 | 0.68 | GPR119 (0.39) | GPR119EIF4EMKNK1MKNK2CYP2C9 | |
| SCHEMBL25669167 | 0.68 | PARP1 (0.40) | — | |
| SCHEMBL375962 | 0.67 | GPR119 (0.61) | GPR119CYP2C9 | |
| SCHEMBL4496039 | 0.65 | HTT (0.35) | GPR119CYP2C9 | |
| SCHEMBL21338846 | 0.63 | OPRL1 (0.50) | CYP2C9 | |
| SCHEMBL4503148 | 0.63 | HTT (0.36) | GPR119EIF4EMKNK1MKNK2CYP2C9 | |
| SCHEMBL13003776 | 0.63 | ALDH1A1 (0.40) | — | |
| SCHEMBL4494380 | 0.62 | ALDH1A1 (0.39) | GPR119EIF4EMKNK1MKNK2 | |
| SCHEMBL288160 | 0.61 | ROCK1 (0.41) | GPR119EIF4EMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189577-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | GPR119 528/4885EIF4E 2045/4885MKNK1 249/4885 |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GPR119 1/4885EIF4E 3779/4885MKNK1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.